Results 251 to 260 of about 981,501 (315)

Correction: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups. [PDF]

J Mol Neurosci
Šebelová D, Menšíková K, Kaiserová M, Satke L, Grambalová Z, Čížková K, Tauber Z, Klíčová K, Hraboš D, Cook SEV, Zapletalová J, Kaňovský P.   +11 more
europepmc   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Functional Pathological Features and Molecular Markers in Alzheimer's Disease. [PDF]

Int J Mol Sci
Park MN, Kim HW, Hong JH, Kim JK, Lee SB, Baek HS, Kwak S, Kwon YJ, Park K, Jeon J, Heo NH, Lee SH, Cho J, Kim S.   +13 more
europepmc   +1 more source

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub, Michele K. York, Roseanne Dobkin, Anuprita R. Nair, Ryan Kurth, David‐Erick Lafontant, Chelsea Caspell‐Garcia, Roy N. Alcalay, Ethan G. Brown, Lana M. Chahine, Christopher Coffey, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Andrew Siderowf, Cristina Simonet, Tanya Simuni, Caroline M. Tanner, Thomas F. Tropea, Aleksandar Videnovic, The Parkinson's Progression Markers Initiative   +24 more
wiley   +1 more source

Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis. [PDF]

J Neuropathol Exp Neurol
Gray MT, Cayrol R, May A, Skaugen JM, Hayek F, Lapointe S, Hawkins CE, Pearce TM, Pratt D, Wiredja D, Toland A, Marker DF.   +11 more
europepmc   +1 more source

Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication. [PDF]

J Neurol
Leclercq V.
europepmc   +1 more source

Cytology at the crossroads: Safeguarding equity in the molecular era. [PDF]

Cytojournal
Díaz Del Arco C.
europepmc   +1 more source

The Role of Cytology, Histology and Molecular Pathology in the Diagnostic Process of Thyroid Nodules. [PDF]

Cancers (Basel)
Ribeiro M, Canberk S, Bongiovanni M.
europepmc   +1 more source

What's new in digital and computational pathology 2026: advances in adoption, standards, AI technologies, and clinical integration. [PDF]

J Pathol Transl Med
Sevim S, Hajar C, Sonawane S.
europepmc   +1 more source